Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its alterations may support either immunosuppression or autoimmunity. This pathological plasticity is supported by evidence indicating that common MDSC-associated targets may be specularly targeted in autoimmunity vs. cancer (12), and there is now hope that understanding autoimmune mechanisms might serve as a lesson for the development of new anticancer therapies. The functional plasticity and therapeutic ductility of these cells (Figure 2) suggest that while MDSC inhibition might succeed as anticancer treatment, their induction is expected to provide therapeutic benefit in autoimmune diseases. FIGURE 2 Figure 2. Schematic role of MDSCs in pathology. Immunological stress induces the expansion of MDSCs that play different roles depending on distinct pathological and microenvironmental contexts. MDSCs are characterized by the strong ability to suppress ...
Publication date: Available online 2 June 2020Source: Pathology - Research and PracticeAuthor(s): Hyeongjoo Kim, Taewan Kim, Gunn Jaygal, Jongsoo Woo, Chang-Jin Kim, Moo-Jun Baek, Dongjun Jeong
Publication date: Available online 2 June 2020Source: Pathology - Research and PracticeAuthor(s): Qian Wu, Weiya Wang, Ping Zhou, Yiyun Fu, Ying Zhang, Yang W. Shao, Lili Jiang
Publication date: Available online 2 June 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Mona Bourg, Adeline Ruyssen-Witrand, Célia Bettiol, Jean Parinaud
ABSTRACT Objective To assess the outcome of an educational nutritional intervention in the quality of diet of women with breast cancer in adjuvant treatment. Methods Women with breast cancer and admitted for surgical treatment were divided in an intervention group (n=18) and a comparison group (n=78), and participated in a nonrandomized clinical trial. Participants were assessed before and after the treatment and/or intervention. A food frequency questionnaire was applied and the quality of diet was calculated using the Brazilian Healthy Eating Index Revised. The educational nutritional intervention lasted 12 months and wa...
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
The Trump administration chose 5 companies as the most likely to produce a vaccine. The tally of new cases is rising in the U.S., partly because of expanded testing. Italy ends travel restrictions.
Publication date: Available online 2 June 2020Source: SeizureAuthor(s): Grace J. Ma, Sanya Yadav, Peter W. Kaplan, Emily Johnson
Italian public health officials and the World Health Organization warn there's no evidence to support claims that SARS-CoV-2 is weakening, as some Italian clinicians have reported.WebMD Health News
Bigfoot Biomedical hasn't let the coronavirus pandemic stand in the way of bringing itsÂ injection-based digitized insulin dosing platform to the U.S. market. If anything, CEO Jeffrey Brewer says the pandemic has "only crystalized the need for medical solutions like ours that facilitate remote care, remote support, and home delivery." The company has raised a total of $55 million to close its series C equity financing.Â Abbott led the round with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management, along with n...
Publication date: Available online 3 June 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Shrirang Vasant Kulkarni, Pankaj P. Rao, C.S. Naidu, N. Pathak, A.K. Singh
More News: Allergy | Allergy & Immunology | Alopecia | Alopecia Areata | Antidoxidants | Arthritis | Aspirin | Autoimmune Disease | Biology | Bladder Cancer | Bone Graft | Brain | Breast Cancer | Breast Carcinoma | Calcium | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Carcinoma | Chemotherapy | Cialis | Clinical Trials | Colon Cancer | Colorectal Cancer | Crohn's Disease | Cytology | Diabetes | Diabetes Type 1 | Disability | Emergency Medicine | Endocrinology | Environmental Health | Epithelial Cancer | Esophagus Cancer | Fortamet | Funding | Gastroenterology | Genetics | Glomeruli | Head and Neck Cancer | Hepatitis | Hepatitis B | Hepatitis C | Hepatocellular Carcinoma | HNSCC | Immunotherapy | Infectious Diseases | Inflammatory Bowel Disease | Insulin | Italy Health | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Lessons | Liver | Liver Cancer | Liver Transplant | Lung Cancer | Lung Transplant | Lupus | Lymphoma | Melanoma | Men | Metformin | Mitochondria | Mitochondrial Disease | Multiple Sclerosis | Myasthenia Gravis | Myeloma | Nephritis | Neurology | Niacin | Non-Small Cell Lung Cancer | Noonan Syndrome | Nutrition | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Parenteral Nutrition | Pathology | Pharyngeal Cancer | Pregnancy | Pregnancy and Breast Cancer | Primary CNS Lymphoma | Psoriasis | Renal Cell Carcinoma | Rheumatoid Arthritis | Rheumatology | Skin | Skin Cancer | Skin Graft | Spinal Cord Injury | Squamous Cell Carcinoma | Staphylococcus Aureus | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Transplants | Tuberculosis | Ulcerative Colitis | Urology & Nephrology | Viagra | Women | Yervoy